Elizabeth Holmes Is Back, and She's Selling Something Way Worse Than Blood
Palo Alto, CA – In a move that shocked absolutely no one with a functional amygdala, Elizabeth Holmes—the human embodiment of a LinkedIn bro who peaked at a Theranos all-hands meeting—has resurfaced. And before you ask, no, she didn't spend her post-prison stint reflecting on the thousands of patients who got bogus blood tests while she perfected her Steve Jobs cosplay. She did what any narcissist with a law degree and a burning need for attention does: she launched a new startup.
Because why fix the healthcare system when you can just sell it a second time?
The company, cryptically named "Aletheia" (Greek for "truth," because of course it is), promises to revolutionize—wait for it—mental health diagnostics. That's right, folks. The woman who convinced billionaires she could run 30 lab tests on a single drop of blood is now claiming she can detect depression, anxiety, and PTSD with a proprietary algorithm and a cheek swab.
I'm not making this up. I wish I was. I'd rather be writing about a golden retriever learning to skateboard, but here we are.
Holmes, fresh off her early release from prison (because apparently, fraud is a gateway to good behavior credits), held a launch event that was less a press conference and more a masterclass in gaslighting. She wore the same black turtleneck, because if it ain't broke, don't fix it—unless it's your legal ethics, in which case, definitely fix that. The stage was bathed in blue light, the music was ominous and cinematic, and she spoke in that low, baritone voice that sounds like a text-to-speech program having a panic attack.
"Aletheia isn't just a product," she said, staring directly into the camera with those dead, reptilian eyes. "It's a paradigm shift. We're not treating the symptoms of mental illness; we're decoding the biological language of the soul."
The audience, a mix of tech bros who've never felt a real emotion and venture capitalists who view empathy as a market inefficiency, ate it up like they were starving.
Let's get one thing straight: this woman is not a scientist. She's a performance artist with a fraudulent medical degree and a pathological inability to blink. Her track record is a masterclass in how to burn $9 billion and leave a trail of ruined lives, including her own ex-boyfriend who's currently doing time for his part in the charade. But sure, let's trust her with our mental health—the one thing we all pretend to care about but secretly just want a pill to fix.
The science, according to the one "independent expert" they trotted out (who was clearly paid more than the GDP of a small island nation), is based on "epigenetic markers" that can be detected via salivary biomarkers. Sounds legit, right? Except the entire methodology is proprietary, which is corporate-speak for "we won't show you our data because we don't have any."
But here's the real kicker, the part that should make your blood boil—pun intended. Aletheia isn't targeting hospitals or doctors. They're going straight to consumers via a sleek app. You'll be able to order a test kit for $299, swab your cheek, mail it in, and get a "comprehensive mental health blueprint" delivered to your phone within 48 hours.
What could possibly go wrong? A woman who overpromised and underdelivered on a grand scale is now in charge of telling you whether you're clinically depressed. The last time she oversaw diagnostics, people with real conditions like HIV and cancer were told they were perfectly healthy. But hey, now she's predicting your mood swings. What's the worst that could happen? You get a false negative for suicidal ideation and end up in a crisis that could've been prevented?
The FDA is already sniffing around, likely asking pointed questions like, "Are you out of your goddamn mind?" But Holmes has a new legal team that specializes in "disruptive regulation navigation," which is just a fancy way of saying they're going to find a loophole the size of the Grand Canyon to get this thing to market before the government can slap a "Does Nothing" sticker on it.
The most infuriating part isn't even the scam itself. It's the cultural amnesia that allows this to happen. We live in a country where a convicted felon can launch a new company and be treated like a phoenix rising from the ashes, rather than a dumpster fire that's legally required to wear an ankle monitor. The media is already framing this as a "redemption arc," because apparently, serving time for defrauding patients and investors is the new prerequisite for a TED Talk.
Meanwhile, actual scientists who've spent decades studying mental health are being pushed aside for a woman whose entire scientific method consists of making intense eye contact and whispering "this will change the world" until people believe her.
I can't wait for the inevitable sequel: Holmes gets outed again, she declares bankruptcy, she files for a new startup called "Epiphany" that promises to cure aging with a homeopathic ear candle, and we all clap like seals because she's "disrupting" something.
Here's a hot take, Elizabeth: If you want to help people, try telling the truth for once. It's a novel concept, but I hear it does wonders for your credibility. Or better yet, just go back to whatever billionaires' compound you're hiding out in and let the rest of us try to forget that you're a walking, talking cautionary tale about the dangers of unchecked charisma and a complete lack of conscience.
Because the last thing we need in this country's mental health crisis is a woman who thinks a cheek swab is a substitute for a soul.
Final Thoughts
As a journalist, the Theranos saga has always struck me as less a story about technology and more a cautionary tale about the intoxicating power of narrative—Holmes sold a myth of Steve Jobs-like genius so convincingly that an entire boardroom of titans abandoned basic skepticism. The real tragedy isn't just the billions lost, but the chilling effect it has on legitimate biotech innovation, where investors now demand proof over promises, making it harder for genuine breakthroughs to secure the funding they desperately need. In the end, her downfall wasn't a failure of science, but a failure of human due diligence, and that’s a lesson that should haunt every boardroom long after her prison sentence is served.